Visiongain Publishes Asthma & COPD Therapies Market Report 2020-2030
11 August 2020
Visiongain has launched a new pharma report Asthma & COPD Therapies Market Report 2020-2030: Forecasts by Treatment (Bronchodilator Monotherapy (Anticholinergics (Spiriva, Atrovent, Eklira, Others), SABA (Ventolin, ProAir, Proventil, Xoponex, Others), LABA (Foradil, Arcapta/Onbrez, Brovana, Serevent, Others)), (Anti-Inflammatory Drugs (Corticosteroids (Pulmicort, Flixotide, QVAR, Asmanex, Others), Anti-Leukotrienes (Singulair, Others), Monoclonal Antibodies (Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab)), Others, (Combination Drugs (Advair, Symbicort, Combivent, Dulera, Relvar/Breo, Others)), by Route of Administration (Oral, Inhaled, Others), by Point of Sale/Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), Geography (North America, Europe, Asia Pacific, Rest of the World) PLUS COVID-19 Impact Scenarios and Profiles of Leading Asthma & COPD Companies.
The global COPD and Asthma Therapeutics market is anticipated to reach US$ xx million in 2030 from its previous value of US$ xx million in 2020. The overall growth rate for the forecast period 2020 to 2030 is predicted to be xx%.
“Increasing pollution in emerging economies has resulted in degradation of air quality which is one of the major reasons for increasing COPD and asthma prevalence amongst children and teenagers. Furthermore, reduction in social stigma on usage of inhalers has resulted in an improved disease management regime across various countries.”
Industry Analyst, Visiongain 2020
Asthma and COPD are chronic conditions that require regular monitoring and frequent changes to medication. In addition, patient adherence to treatment and inhaler technique affects clinical outcomes. Improvements in these areas could increase demand for asthma and COPD therapies and have a positive effect on market growth. Recently, steps have been undertaken by the healthcare agencies and private companies across the world in initiating telehealth as a mode of management for asthma and COPD patients.
One of the major trials of this was undertaken by Novartis in the UK in 2012, in collaboration with multiple healthcare agencies. Novartis developed their inhaler, Breezhaler, into an electronic inhaler (eBreezhaler). The inhaler has an electronic chip inside it, which monitors the number of times the device has been used and transmits the data into a telehealth system which can be accessed by the physician. This technique allows the physician to observe the patient adherence and monitor their conditions remotely and in real time. It should reduce the frequency of hospitalization and improve adherence to treatment.
COPD is a leading cause of death in the United States which affects over 18 million Americans. More than 65 million people around the world have moderate or severe COPDs and experts predict that over the next 50 years this number will continue to rise worldwide. More than.5 million Americans were diagnosed with chronic bronchitis in 2019, and almost 75 per cent of cases involved people over 45 years of age. Throughout the United States, women develop recurrent bronchitis at almost double the rate of males. Over the last 12 months, 5.9 million people were infected with recurrent bronchitis over 2016 as compared to 3 million men who had been infected around this period.
Asia has seen strong economic development and a declining climatic condition in recent years, with a rise in outbreak proportions of allergic diseases. For several Asian countries in particular China and India, air pollutant rates are considerably higher than in developing countries. In addition, combustion of agricultural, traffic-related and domestic waste, indoor chemicals and tobacco emissions are significant sources of air contaminants, with increased pressure on respiratory allergies. Such factors are likely to flourish the market for drugs over the forecast period. Some of the major companies operating in this market are AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Merck, F. Hoffmann-La Roche AG among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033